Improving outcomes for people with skin tumours including melanoma

More documents

Recommendations

Info

Improving Outcomes for People with Skin Tumours including Melanoma Appendix 5 • CancerBACUP • Changing Faces • Chartered Society of Physiotherapy • Clatterbridge Centre for Oncology NHS Trust • Cochrane Skin Group • College of Occupational Therapists • Coloplast Limited • ConvaTec • Co-operative Pharmacy Association • Countess of Chester Hospitals NHS Trust A5 • Department of Health • DiaSorin Limited • Dudley Group of Hospitals NHS Trust, The • East Cambridgeshire and Fenland Primary Care Trust • Eisai Limited • Elan Pharmaceuticals Ltd • Faculty of Public Health • Frimley Park Hospital NHS Trust • Galderma (UK) Ltd • Gloucestershire Hospitals NHS Trust • Gorlin Syndrome Group • Guerbet Laboratories Ltd • Guy’s & St Thomas’ NHS Trust • Health Development Agency 148 National Institute for Health and Clinical Excellence
• Healthcare Commission • Help Adolescents with Cancer • Help the Hospices Improving Outcomes for People with Skin Tumours including Melanoma Appendix 5 • Institute of Sport and Recreation Management • Johnson & Johnson Medical • Joint Committee on Palliative Medicine • Leeds North East PCT • Leeds Teaching Hospitals NHS Trust • Macmillan Cancer Relief • Mansfield District PCT • Marie Curie Cancer Care • Medeus Pharma Limited • Medicines and Healthcare Products Regulatory Agency (MHRA) A5 • Mid Staffordshire General Hospitals NHS Trust • Middlesbrough Primary Care Trust • Mole Clinic Ltd, The • National Alliance of Childhood Cancer Parent Organisations • National Association of Assistants in Surgical Practice, The • National Cancer Alliance • National Cancer Network Clinical Directors Group • National Cancer Research Institute (NCRI) Clinical Studies Group • National Council for Disabled People, Black, Minority and Ethnic Community (Equalities) • National Kidney Federation (NFK) • National Patient Safety Agency Guidance on cancer services: skin tumours including melanoma 149
Page 1 and 2:
NHS National Institute for Health a
Page 3 and 4:
Contents Improving Outcomes for Peo
Page 5 and 6:
Patient information ...............
Page 7 and 8:
Resource implications .............
Page 9 and 10:
Foreword Improving Outcomes for Peo
Page 11 and 12:
- referral - review of patient care
Page 13 and 14:
early detection have been published
Page 15 and 16:
The epidemiology of skin cancers an
Page 17 and 18:
The incidence of MM increases with
Page 19 and 20:
Figure 5. Mortality from MM, Englan
Page 21 and 22:
Figure 8. Incidence of NMSC, Englan
Page 23 and 24:
Risk factors for skin cancer As ski
Page 25 and 26:
Figure 12. Rates of episodes of inp
Page 27 and 28:
Two-week wait data Urgent skin canc
Page 29 and 30:
• Improving the experience of car
Page 31 and 32:
12. National Institute for Clinical
Page 33 and 34:
Patient-centred care Improving Outc
Page 35 and 36:
This document and the NICE Referral
Page 37 and 38:
A checklist may be used by healthca
Page 39 and 40:
Quality assurance Surveys of patien
Page 41 and 42:
One cross-sectional study found tha
Page 43 and 44:
One RCT conducted with patients wit
Page 45 and 46:
• Every skin cancer MDT having ac
Page 47 and 48:
to estimate a separate cost for ser
Page 49 and 50:
department or they may be referred
Page 51 and 52:
The 2-week waiting time standard an
Page 53 and 54:
The local hospital skin cancer mult
Page 55 and 56:
A function of the LSMDT is to audit
Page 57 and 58:
• lymphoedema therapists • phar
Page 59 and 60:
SSMDT meetings should be at least f
Page 61 and 62:
As set out in the section on ‘Arr
Page 63 and 64:
• Palliative care specialists. Si
Page 65 and 66:
Videoconferencing and teleconferenc
Page 67 and 68:
A basic knowledge of skin cancer hi
Page 69 and 70:
B. Anticipated benefits At present,
Page 71 and 72:
One systematic review (of the abili
Page 73 and 74:
One retrospective study compared pa
Page 75 and 76:
• Critical incidents where treatm
Page 77 and 78:
Network-wide protocols It is not po
Page 79 and 80:
Initial investigation, diagnosis, s
Page 81 and 82:
Figure 14. Skin lesion - patient pa
Page 83 and 84:
curettage (as recommended in BAD gu
Page 85 and 86:
Diclofenac 3% gel (Solaraze) is lic
Page 87 and 88:
Histopathology services for skin ca
Page 89 and 90:
Patients with anogenital Bowen’s
Page 91 and 92:
B. Anticipated benefits Better-qual
Page 93 and 94:
One RCT compared teledermatology wi
Page 95 and 96:
One systematic review based upon 12
Page 97 and 98:
Expert review evidence suggests tha
Page 99 and 100: Immunotherapy An RCT comparing allo
Page 101 and 102: • Adherence to treatment protocol
Page 103 and 104: F. Research priorities • Given th
Page 105 and 106: For patients with low-risk BCC or S
Page 107 and 108: Follow-up for patients after treatm
Page 109 and 110: C. Evidence Evidence exists that ea
Page 111 and 112: One observational study found that
Page 113 and 114: The written and photographic inform
Page 115 and 116: Genetic predisposition to MM may al
Page 117 and 118: patients with cutaneous lymphoma sh
Page 119 and 120: A. Recommendations Generic recommen
Page 121 and 122: Cutaneous lymphoma All patients sho
Page 123 and 124: Children and young people with skin
Page 125 and 126: Gorlin’s syndrome Two expert revi
Page 127 and 128: Process • Audit of adherence to p
Page 129 and 130: • Cutaneous lymphoma is so rare t
Page 131 and 132: Dermal and subcutaneous tumours Aty
Page 133 and 134: c) The guidance will also refer to
Page 135 and 136: 4.2.2 Healthcare settings and servi
Page 137 and 138: Referral from the Department of Hea
Page 139 and 140: Table A1. Summary of service option
Page 141 and 142: For those cancer networks with part
Page 143 and 144: Appendix 4 How this guidance manual
Page 145 and 146: Appendix 5 People and organisations
Page 147 and 148: Professor Julia Newton-Bishop Mr Ba
Page 149: • Bristol South and West PCT •
Page 153 and 154: • Royal College of Surgeons of En
Page 155 and 156: Appendix 5.3 Researchers carrying o
Page 157 and 158: Appendix 5.4 Expert advisers to the
Page 159 and 160: Appendix 5.5 Report* commissioned t
Page 161 and 162: Appendix 6 Glossary of terms Improv
Page 163 and 164: Chemoprophylaxis The use of a drug
Page 165 and 166: Electrodesiccation A surgical metho
Page 167 and 168: Immunotherapy Treatment by stimulat
Page 169 and 170: Morbidity A diseased condition or s
Page 171 and 172: Prognosis A prediction of the likel
Page 173 and 174: Systemic therapy Treatment that rea
Page 175 and 176: KS LHB LSMDT MCC MDT MM MRI NCC-C N
show all

Improving outcomes for people with skin tumours including melanoma

Create successful ePaper yourself

Delete template?

Save as template?